Medizone International announced it has been granted its fourth patent for AsepticSure, its pioneering enclosed space room disinfection system. The U.S. Patent and Trademark Office has issued U.S. Patent number 8,636,951, “Bio-Terrorism Counteraction Using Ozone and Hydrogen Peroxide,” to the company.
This latest patent follows on the heels of patent protection for Medizone’s healthcare-related patent applications. The company has now been awarded a patent for its government variant of AsepticSure, which is intended to be used by defense agencies as a response to biological attacks on critical buildings, infrastructure, and resources.
Medizone International has successfully eliminated bacillus atropheus and bacillus subtilis at its Innovation Park, Queens University laboratories. Both of these bacteria are globally recognized study surrogates for anthrax, which is one of the most difficult weaponized pathogens to kill. The ability to eliminate these anthrax surrogates with the AsepticSure technology approaches assurance that Medizone International now has the ability to restore critical public infrastructure to service after a biological attack without damaging crucial and costly equipment, such as communication systems. This problem has plagued militaries for decades without, until now, a solution.
“To now have patent protection granted for this system,” said Medizone CEO Edwin Marshall, “should allow the company protected access to a potentially lucrative government market due to the unique capability of AsepticSure’s government variant.”
For more information, visit www.medizoneint.com
Let us hear your thoughts below: